Form 4: Immix Biopharma Director Jason Hsu Reports Significant Beneficial Ownership and New Stock Option Grant

Immix Biopharma, Inc. Director Jason Hsu has filed a Form 4 detailing his beneficial ownership of common stock and the acquisition of new stock options.

Summary

• Jason Hsu, a Director at Immix Biopharma, Inc. (IMMX), reported direct beneficial ownership of 893,000 shares of Common Stock.
• Mr. Hsu also reported indirect beneficial ownership of 3,915,913 shares of Common Stock through VERITAS LIBERABIT VOS, LLC, where he is the Sole Member, disclaiming beneficial ownership except to the extent of his pecuniary interest.
• An additional 50,000 shares of Common Stock are indirectly beneficially owned through Signature Collection Properties, LLC, where Mr. Hsu is also the Sole Member, with a similar disclaimer.
• On June 20, 2025, Mr. Hsu acquired 33,000 stock options with an exercise price of $2.24 per share.
• These stock options will vest in twelve equal monthly installments following the grant date, contingent upon Mr. Hsu's continued service on the Board of Directors.
• The stock options have an expiration date of June 20, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as a director receiving stock options aligns their interests with shareholders and indicates continued commitment, which is generally viewed favorably by the market.

Positives

• The grant of 33,000 stock options to Director Jason Hsu aligns his interests with shareholders, incentivizing long-term performance.
• The vesting schedule tied to continued service on the Board of Directors indicates a commitment to the company's future.

Future Outlook

The stock options granted to Director Jason Hsu are subject to a twelve-month vesting schedule, contingent on his continued service on the Board of Directors, indicating an expectation of his ongoing involvement and contribution to the company.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for insiders (directors, officers, and 10% owners) to report changes in their beneficial ownership of company securities. It provides transparency into insider transactions, which can sometimes signal management's confidence or concerns about the company's future prospects.

Related Party Transactions

• Jason Hsu's indirect beneficial ownership through VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC, where he is the Sole Member, represents related party holdings, as is standard for beneficial ownership reporting.

Stakeholder Impact

• Shareholders may view the grant of stock options to a director as a positive signal, indicating management's confidence and alignment with shareholder interests.
• The vesting schedule tied to continued service reinforces the director's commitment to the company's long-term success.

Next Steps

• The 33,000 stock options granted to Jason Hsu will vest in twelve equal monthly installments following the grant date of June 20, 2025, subject to his continued service on the Board of Directors.

Key Dates

Keywords

Immix Biopharma, IMMX, Jason Hsu, Form 4, Beneficial Ownership, Stock Option, Director, Insider Transaction, Equity Compensation